LAMA add‐on showed no clear difference in all‐cause serious adverse events 24 weeks compared with ICS alone (low certainty).
Fluticasone/salmeterol (FPS) showed no clear difference in adverse events—'serious' Duration of two years1 compared with placebo (low certainty).
Mometasone/formoterol (MF/F) showed no clear difference in adverse events—serious—400/103 Duration of six months compared with placebo (low certainty).
Mometasone/formoterol (MF/F) showed no clear difference in adverse events—serious—200/103 Duration of six months compared with placebo (low certainty).
Budesonide/formoterol (BDF) showed no clear difference in adverse events—'serious'—320/94 Duration of 10 months3 compared with placebo (low certainty).
Budesonide/formoterol (BDF) showed no clear difference in adverse events—'serious'—160/94 Duration of nine months 3 compared with placebo (low certainty).
The intervention showed no clear difference in adverse events－serious Mometasone/formoterol (MF/F) versus… (low certainty).
The intervention showed no clear difference in adverse events－serious Fluticasone/salmeterol (FPS) versus… (low certainty).
Fixed‐dose combination aclidinium/formoterol leads to lower adverse events (not including serious adverse events): number of… compared with formoterol (high certainty).
Fixed‐dose combination aclidinium/formoterol showed no clear difference in adverse events (not including serious adverse events): number of… compared with placebo (moderate certainty).
Fixed‐dose combination aclidinium/formoterol showed no clear difference in adverse events (not including serious adverse events): number of… compared with aclidinium alone (moderate certainty).
It is very uncertain whether the intervention changes adverse events－serious events Budesonide/formoterol (BDF) versus… (very low certainty).